View Item 

Show simple item record

Report of the American Society of Transplantation Conference on Immunosuppressive Drugs and the Use of Generic Immunosuppressants

dc.contributor.authorAlloway, Rita R.en_US
dc.contributor.authorIsaacs, Rossen_US
dc.contributor.authorLake, Kathleen D.en_US
dc.contributor.authorHoyer, Peter F.en_US
dc.contributor.authorFirst, Royen_US
dc.contributor.authorHelderman, Harolden_US
dc.contributor.authorBunnapradist, Suphamaien_US
dc.contributor.authorLeichtman, Alan B.en_US
dc.contributor.authorBennett, M. Williamen_US
dc.contributor.authorTejani, Amiren_US
dc.contributor.authorTakemoto, Steven K.en_US
dc.date.accessioned2010-06-01T18:27:02Z
dc.date.available2010-06-01T18:27:02Z
dc.date.issued2003-10en_US
dc.identifier.citationAlloway, Rita R.; Isaacs, Ross; Lake, Kathleen; Hoyer, Peter; First, Roy; Helderman, Harold; Bunnapradist, Suphamai; Leichtman, Alan; Bennett, M. William; Tejani, Amir; Takemoto, Steven K. (2003). "Report of the American Society of Transplantation Conference on Immunosuppressive Drugs and the Use of Generic Immunosuppressants." American Journal of Transplantation 3(10): 1211-1215. <http://hdl.handle.net/2027.42/71658>en_US
dc.identifier.issn1600-6135en_US
dc.identifier.issn1600-6143en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/71658
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=14510694&dopt=citationen_US
dc.format.extent66803 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherMunksgaard International Publishersen_US
dc.publisherBlackwell Publishing Ltden_US
dc.rightsBlackwell Munksgaard 2003en_US
dc.subject.otherBioequivalenceen_US
dc.subject.otherCyclosporinen_US
dc.subject.otherGenericen_US
dc.subject.otherTransplantationen_US
dc.titleReport of the American Society of Transplantation Conference on Immunosuppressive Drugs and the Use of Generic Immunosuppressantsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherUniversity of Cincinnati, College of Medicine, Cincinnati OHen_US
dc.contributor.affiliationotherCenter for Improvement of Minority Health, University of Virginia Health System, Charlottesville, VAen_US
dc.contributor.affiliationotherPediatric Nephrology, University of Essen, Essen, Germanyen_US
dc.contributor.affiliationotherFujisawa Healthcare Inc, Deerfield, ILen_US
dc.contributor.affiliationotherVanderbilt Transplant Center, Nashville, TNen_US
dc.contributor.affiliationotherCedars-Sinai Medical Center, Los Angeles, CAen_US
dc.contributor.affiliationotherLegacy Good Samaritan Hospital, Portland, ORen_US
dc.contributor.affiliationotherNew York Medical College, Valhalla, NYen_US
dc.contributor.affiliationotherDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, CAen_US
dc.identifier.pmid14510694en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/71658/1/j.1600-6143.2003.00212.x.pdf
dc.identifier.doi10.1046/j.1600-6143.2003.00212.xen_US
dc.identifier.sourceAmerican Journal of Transplantationen_US
dc.identifier.citedreferenceWelage LS, Kirking DM, Ascione FJ, Gaither CA. Understanding the scientific issues embedded in the generic drug approval process. J Am Pharm Assoc (Wash) 2001; 41: 856.en_US
dc.identifier.citedreferenceCuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther 2000; 14: 1009.en_US
dc.identifier.citedreferenceHaroldson JA, Somerville KT, Carlson S, Hanson J, Emery RW, Lake KD. A retrospective assessment of safety, efficacy, and pharmacoeconomics of generic azathioprine in heart-transplant recipients. J Heart Lung Transplant 2001; 20: 372.en_US
dc.identifier.citedreferenceNightingale SL, Morrison JC. Generic drugs and the prescribing physician. JAMA 1987; 258: 1200.en_US
dc.identifier.citedreferenceHenderson J, Dighe S, Williams R. Subject selection and management in bioequivalence studies. Clin Res Reg Aff 1992; 9: 71.en_US
dc.identifier.citedreferenceGleiter CH, Gundert-Remy U. Bioinequivalence and drug toxicity. How great is the problem and what can be done? Drug Saf 1994; 11: 1.en_US
dc.identifier.citedreferenceRheinstein PH. The generic drug approval process. Am Fam Physician 1993; 48: 1357.en_US
dc.identifier.citedreferenceNation RL, Sansom LN. Bioequivalence requirements for generic products. Pharmacol Ther 1994; 62: 41.en_US
dc.identifier.citedreferenceSkelly JP. Bioavailability and bioequivalence. J Clin Pharmacol 1976; 16: 539.en_US
dc.identifier.citedreferencePatnaik R, Lesko LJ, Chan K, Williams RL. Bioequivalence assessment of generic drugs. an American point of view. Eur J Drug Metab Pharmacokinet 1996; 21: 159.en_US
dc.identifier.citedreferenceChristians U, First MR, Benet LZ. Recommendations for bioequivalence testing of cyclosporine generics revisited. Ther Drug Monit 2000; 22: 330.en_US
dc.identifier.citedreferenceGarbe E, Rohmel J, Gundert-Remy U. Clinical and statistical issues in therapeutic equivalence trials. Eur J Clin Pharmacol 1993; 45: 1.en_US
dc.identifier.citedreference13.  Federal Food, Drug, Cosmetic Act 21USC, 355 (j)&(B).en_US
dc.identifier.citedreferenceMarzo A, Balant LP. Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products. Arzneimittelforschung 1995; 45: 109.en_US
dc.identifier.citedreference15.  Bioavailability and Bioequivalence Requirements. 21 CFR 320. 1 – 63, 2001.en_US
dc.identifier.citedreferenceBenet LZ, Goyan JE. Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy 1995; 15: 433.en_US
dc.identifier.citedreferenceMin DI, Hwang GC, Bergstrom S et al.. Bioavailability and patient acceptance of cyclosporine soft gelatin capsules in renal allograft recipients. Ann Pharmacother 1992; 26: 175.en_US
dc.identifier.citedreferenceZehnder C, Beveridge T, Nuesch E, Abisch A, Thiel G. Cyclosporine A capsules: bioavailability and clinical acceptance study in renal transplant patients. Transplant Proc 1988; 20 ( 2 Suppl. 2 ): 641.en_US
dc.identifier.citedreferenceBleck JS, Nashan B, Christians U, Schottmann R, Wonigeit K, Sewing KF. Single dose pharmacokinetics of ciclosporin and its main metabolites after oral ciclosporin as oily solution or capsule. Arzneimittelforschung 1990; 40: 62.en_US
dc.identifier.citedreferenceNashan B, Bleck J, Wonigeit K et al.. Effect of the application form of cyclosporine on blood levels: comparison of oral solution and capsules. Transplant Proc 1988; 20 ( 2 Suppl. 2 ): 637.en_US
dc.identifier.citedreferenceHilbrands LB, Hoitsma AJ, van den Berg JW, Koene RA. Cyclosporin A blood levels during use of cyclosporin as oral solution or in capsules: comparison of pharmacokinetic parameters. Transplant Int 1991; 4: 125.en_US
dc.identifier.citedreferenceBennett WM, Olyaei AJ. Pharmacoeconomics of immunosuppressive agents in renal transplant recipients. Transplant Proc 1999; 31 ( 3A (Suppl.): 6S.en_US
dc.identifier.citedreferenceCoukell AJ, Plosker GL. Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation. Pharmacoeconomics 1998; 14: 691.en_US
dc.identifier.citedreferenceAlloway RR. Generic immunosuppressant use in solid organ transplantation. Transplant Proc 1999; 31 ( 3A (Suppl.): 2S.en_US
dc.identifier.citedreferenceRoza A, Tomlanovich S, Merion R et al.. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation. Transplantation 2002; 74: 1013.en_US
dc.identifier.citedreferenceTomlanovich S, Pollack R, Roza A et al.. A pharmacokinetic conversion study of Abbott cyclosporine and NEORAL in stable renal transplant recipients. North Chicago, IL: Abbott Laboratories, Inc., 1999; 60064: 99J–031 – 99J–8028.en_US
dc.identifier.citedreferenceLindholm A, Welsh M, Rutzky L, Kahan BD. The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss. Transplantation 1993; 55: 985.en_US
dc.identifier.citedreferenceMerion RM, White DJ, Thiru S, Evans DB, Calne RY. Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med 1984; 310: 148.en_US
dc.identifier.citedreferenceNeylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1997; 64: 1277.en_US
dc.identifier.citedreferenceWatkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997; 27: 161.en_US
dc.identifier.citedreferenceMalhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice–felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001; 69: 14.en_US
dc.identifier.citedreferenceWatkins P, Leichtman A. The molecular basis of cyclosporin a metabolism, pharmacokinetics and drug interactions. Graft 1999; 2: 177.en_US
dc.identifier.citedreferenceKasiske BL, Cohen D, Lucey MR, Neylan JF. Payment for immunosuppression after organ transplantation: American Society of Transplantation. JAMA 2000; 283: 2445.en_US
dc.identifier.citedreferenceBurckart G, Venkataramanan R, Starzl T, Ptachcinski R, Gartner C, Rosenthal T. Cyclsoporine clearance in children following organ transplantation. J Clin Pharmacol 1985; 24: 412.en_US
dc.identifier.citedreferenceVenkataramanan R, Burckhart GJ, Ptachcinski RJ. Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation. Semin Liver Dis 1985; 5: 357.en_US
dc.identifier.citedreferenceYee GC, Lennon TP, Gmur DJ, Kennedy MS, Deeg HJ. Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther 1986; 40: 438.en_US
dc.identifier.citedreferenceHoyer PF, Brodehl J, Ehrich JH, Offner G. Practical aspects in the use of cyclosporin in paediatric nephrology. Pediatr Nephrol 1991; 5: 630.en_US
dc.identifier.citedreferenceIsaacs RB. Optimal transplant immunosuppression: a case of the haves and have nots? Am J Kidney Dis 2001; 37: 160.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1600-6143.2003.00212.x.pdf
Size:
65.23KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.